Monocyte Chemoattractant Protein-1 in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis: Biomarker Potential and Association with Polymorphisms in the MCP-1 and the CC Chemokine Receptor-2 Gene

Table 3

Distribution of genotypes of the -2518 MCP-1 and the CCR2-V64I polymorphism.

	Patients versus controls		ANCA specificity			Diagnosis		Prognosis
	Patients	Healthy controls	MPO	PR3	Negative	GPA	MPA	Severe	Nonsevere
MCP-1 -2518 A/G
A/A	54.5% ()	50% ()	63.2% ()	50.0% ()	0% ()	56.4% ()	46.7% ()	87.5% ()	39.5% ()
A/G	41.8% ()	50% ()	36.8% ()	47.1% ()	0% ()	38.5% ()	53.3% ()	12.5% ()	59.3% ()
G/G	3.6% ()	0% ()	0% ()	2.9% ()	100% ()	5.1% ()	0% ()	0% ()	5.3% ()
CCR2; V64I
G/G	84.2% ()	86.9% ()	80.0% ()	88.6% ()	100% ()	90.2% ()	73.3% ()	84.2% ()	86.5% ()
G/A	14.0% ()	12.0% ()	20.0% ()	8.5% ()	0% ()	7.3% ()	26.7% ()	15.8% ()	10.8% ()
A/A	1.8% ()	1.1% ()	0% ()	2.9% ()	0% ()	2.4% ()	0% ()	0% ()	(2.7% ()

MCP-1: monocyte chemoattractant protein-1; CCR2: CC chemokine receptor 2; MPO: myeloperoxidase; PR3: proteinase 3; GPA: granulomatosis polyangitis; MPA: microscopic polyangitis. Patients with severe prognosis had significantly higher frequency of the MCP-1 -2518 A/A genotype than patients with less severe prognosis ().